Key Takeaways
- Humana delivered adjusted EPS of $10.31 for Q1, surpassing analyst forecasts of $10.19–$10.20
- Shares tumbled as much as 7.4% in premarket sessions despite outperforming earnings expectations
- The company maintained its full-year adjusted EPS target at $9 while reducing reported profit guidance to $8.36 from $8.89
- Declining Medicare Advantage Star Ratings for 2026 are pressuring bonus revenue and overall profitability
- Management highlighted a widening disparity between medical expenditures and government reimbursement rates
Humana delivered first-quarter results that exceeded Wall Street projections on Wednesday, yet the market response was decidedly negative. Shares plunged as much as 7.4% in premarket sessions after the healthcare insurance giant declined to raise its annual profit forecast while competitors moved theirs higher.
The company reported adjusted earnings of $10.31 per share, surpassing consensus estimates that ranged between $10.19 and $10.20. Revenue climbed to $39.65 billion from $32.11 billion in the year-ago period, also exceeding analyst projections of $39.37 billion.
Despite the solid performance, market participants remained unimpressed.
According to Morningstar analyst Julie Utterback, market participants likely anticipated an upward revision to guidance following such a robust quarterly performance. That revision never materialized.
The insurer maintained its full-year adjusted earnings projection at a minimum of $9 per share. However, on a GAAP basis, management actually lowered expectations — revising the forecast down to at least $8.36 per share from the prior target of at least $8.89.
The downward revision accounts for expenses related to a comprehensive transformation initiative, encompassing employee severance packages, asset write-downs, and external consulting fees.
Star Rating Pressure Creates Financial Headwinds
A critical factor influencing Humana’s performance is the company’s deteriorating Medicare Advantage Star Ratings for the 2026 performance year. These government-issued ratings, which range from one to five stars, directly determine eligibility for federal bonus payments. Diminished ratings translate to reduced bonus income.
Management has been communicating this challenge for several quarters. Net income per share for the first quarter registered at $9.83, down from $10.30 in the comparable prior-year period — a direct consequence of this ongoing pressure.
CEO Jim Rechtin indicated that healthcare utilization patterns and associated costs remained consistent with internal projections. However, he acknowledged that the difference between actual care costs and federal reimbursement levels has expanded compared to the previous year.
“Every year we’re going to step back and look at our whole portfolio,” Rechtin said.
Medical Loss Ratio Shows Positive Performance
One encouraging development: Humana’s insurance division benefit ratio — representing the percentage of premium revenue allocated to medical claims — registered at 89.4% during Q1. This figure came in better than the company’s internal forecast of just under 90% and outperformed Wall Street’s 89.7% estimate.
For insurers, a lower ratio indicates superior operational performance. Readings below 90% are typically viewed as evidence of effective cost management.
Looking to Q2, Humana anticipates this metric will increase to slightly above 91%, suggesting some emerging cost pressures on the horizon.
The organization also observed that aggregate medical and pharmacy cost trends are performing modestly better than anticipated, which Cantor analyst Sarah James identified as among the limited positive aspects of the quarterly report.
Nevertheless, James expressed reservations. “HUM has several signals that the back-half of the year could be difficult to manage,” she stated, characterizing the premarket decline as “a warning sign.”
Humana indicated it will make benefit adjustments as necessary to preserve stable profit margins. The federal government announced earlier this month it would increase Medicare Advantage reimbursement rates by an average of 2.48% for the 2027 plan year.
Shares were trading down approximately 2% in premarket activity after the initial 7.4% decline.
